- Home
- SDHY vs ALT Comparison
SDHY vs ALT Comparison
Compare SDHY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDHY | ALT |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.3M | 377.4M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | SDHY | ALT |
|---|---|---|
| Price | $15.17 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.89 |
| AVG Volume (30 Days) | 64.7K | ★ 3.7M |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | ★ 8.46% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 1.07 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $14.67 | $1.60 |
| 52 Week High | $16.89 | $6.44 |
Technical Indicators
Market Signals| Indicator | SDHY | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 26.24 |
| Support Level | $14.87 | N/A |
| Resistance Level | $16.34 | $3.35 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 13.87 | 11.90 |
Price Performance
Historical ComparisonAbout SDHY PGIM Short Duration High Yield Opportunities Fund
PGIM Short Duration High Yield Opportunities is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It mainly invests in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments (including derivatives) with similar economic characteristics.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.